{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:33:39Z","timestamp":1790775219815,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1241450"],"award-info":[{"award-number":["1241450"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigacion y Desarrollo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tem.2026.01.008","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:27:09Z","timestamp":1774409229000},"page":"815-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["MetALD at the crossroads of metabolic and alcohol-related liver disease"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-2255","authenticated-orcid":false,"given":"Gustavo","family":"Ayares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-4930","authenticated-orcid":false,"given":"Luis Antonio","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-396X","authenticated-orcid":false,"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0499-4191","authenticated-orcid":false,"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2026.01.008_bb0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis \u2013 aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0015","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3350\/cmh.2024.0835","article-title":"Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021","volume":"31","author":"Danpanichkul","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0025","doi-asserted-by":"crossref","first-page":"C1637","DOI":"10.1152\/ajpcell.00951.2024","article-title":"Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease","volume":"328","author":"Kuchay","year":"2025","journal-title":"Am. J. Phys. Cell Physiol."},{"key":"10.1016\/j.tem.2026.01.008_bb0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/jgh.16282","article-title":"Alcohol and the mechanisms of liver disease","volume":"38","author":"Chen","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","article-title":"The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease","volume":"20","author":"D\u00edaz","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0040","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fmed.2020.00448","article-title":"Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities","volume":"7","author":"Idalsoaga","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.tem.2026.01.008_bb0045","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ueg2.70072","article-title":"The rising global burden of MASLD and other metabolic diseases (2000\u20132021)","volume":"13","author":"Danpanichkul","year":"2025","journal-title":"United European Gastroenterol. J."},{"key":"10.1016\/j.tem.2026.01.008_bb0050","article-title":"An expert consensus delphi panel in metabolic dysfunction- and alcohol-associated liver disease: opportunities and challenges in clinical practice","author":"Diaz","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0055","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0060","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000828","article-title":"Metabolic dysfunction and alcohol-associated liver disease: a narrative review","volume":"16","author":"Dunn","year":"2025","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.tem.2026.01.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70017","article-title":"MetALD: new perspectives on an old overlooked disease","volume":"45","author":"Ayares","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2026.01.008_bb0070","article-title":"MetALD: clinical aspects, pathophysiology and treatment","volume":"7","author":"Gratac\u00f3s-Gin\u00e8s","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tem.2026.01.008_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44355-024-00014-8","article-title":"Metabolic and alcohol-associated liver disease (MetALD): a representation of duality","volume":"2","author":"Leal-Lassalle","year":"2025","journal-title":"NPJ Gut Liver"},{"key":"10.1016\/j.tem.2026.01.008_bb0080","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2468-1253(23)00206-6","article-title":"MetALD: new opportunities to understand the role of alcohol in steatotic liver disease","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0085","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.jhep.2025.06.026","article-title":"Krag A reframing the spectrum of steatotic liver disease as a dynamic concept","volume":"83","author":"Younossi","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156101","article-title":"Prevalence, characteristics and outcomes of patients with metabolic and alcohol related\/associated liver disease (MetALD): a systematic review and meta-analysis","volume":"163","author":"Tampaki","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.tem.2026.01.008_bb0095","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.cgh.2025.02.006","article-title":"High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis","volume":"23","author":"Ho","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0100","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease","volume":"77","author":"Staufer","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","article-title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD","volume":"10","author":"Krag","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0110","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2468-1253(25)00187-6","article-title":"Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study","volume":"10","author":"Torp","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0115","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0120","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamainternmed.2025.1809","article-title":"Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease","volume":"185","author":"Ochoa-Allemant","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.tem.2026.01.008_bb0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","article-title":"MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up","volume":"81","author":"Kwak","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/apt.18286","article-title":"Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: a nationwide cohort study","volume":"60","author":"Park","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2026.01.008_bb0135","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/liv.15939","article-title":"Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence","volume":"44","author":"Ciardullo","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2026.01.008_bb0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/HEP.0000000000000914","article-title":"Waitlisting and liver transplantation for MetALD in the United States: an analysis of the UNOS national registry","volume":"81","author":"Ochoa-Allemant","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41575-024-01022-y","article-title":"The steatotic liver disease burden paradox: unravelling the key role of alcohol","volume":"22","author":"Torp","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0150","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1186\/1471-2458-14-1297","article-title":"Drinking pattern is more strongly associated with under-reporting of alcohol consumption than socio-demographic factors: evidence from a mixed-methods study","volume":"14","author":"Boniface","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.tem.2026.01.008_bb0155","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.tem.2026.01.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/alcalc\/agae048","article-title":"AUDIT C compared to PEth in middle-aged volunteers","volume":"59","author":"Fredriksson","year":"2024","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.tem.2026.01.008_bb0165","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s40429-021-00402-7","article-title":"Blood biomarkers of alcohol use: a scoping review","volume":"8","author":"Harris","year":"2021","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.tem.2026.01.008_bb0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2025.07.019","article-title":"Phosphatidylethanol in steatotic liver disease","volume":"83","author":"Torp","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2025.04.019","article-title":"Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes","volume":"83","author":"Vaz","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0180","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.18506","article-title":"Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study","volume":"61","author":"Tavaglione","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2026.01.008_bb0185","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","article-title":"Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification","volume":"83","author":"Tavaglione","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0190","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.14309\/ajg.0000000000003178","article-title":"Using phosphatidylethanol as an adjunct to self-reported alcohol use improves identification of liver fibrosis risk","volume":"120","author":"Murnane","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tem.2026.01.008_bb0195","article-title":"Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake","volume":"7","author":"Hansen","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tem.2026.01.008_bb0200","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41575-025-01120-5","article-title":"Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease","volume":"22","author":"Diaz","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0205","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/j.gastro.2025.07.007","article-title":"Emerging role of phosphatidylethanol testing in clinical practice for the identification of steatotic liver disease subtypes: is this the new standard?","volume":"169","author":"Loomba","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2026.01.008_bb0210","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101903","article-title":"Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American Working Group","volume":"30","author":"Diaz","year":"2025","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0225","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0230","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0235","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.01.008_bb0240","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/00365521.2025.2454247","article-title":"The use of ELF in predicting liver fibrosis prevalence and fibrosis progression in the general population","volume":"60","author":"Saarinen","year":"2025","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.tem.2026.01.008_bb0245","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","article-title":"Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort","volume":"81","author":"Oh","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000718","article-title":"Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)","volume":"9","author":"D\u00edaz","year":"2025","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tem.2026.01.008_bb0255","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary","volume":"67","author":"European Association for the Study of the Liver","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2026.01.008_bb0260","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/apt.70012","article-title":"The lipidomic profile discriminates between MASLD and MetALD","volume":"61","author":"Schneider","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2026.01.008_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101432","article-title":"Concise review of lipidomics in nonalcoholic fatty liver disease","volume":"49","author":"B\u00e9land-Bonenfant","year":"2023","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tem.2026.01.008_bb0270","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/a-2630-0952","article-title":"MetALD: genetic factors and clinical outcomes","volume":"45","author":"Israelsen","year":"2025","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tem.2026.01.008_bb0275","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tem.2026.01.008_bb0280","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/HEP.0000000000000935","article-title":"MetALD: does it require a different therapeutic option?","volume":"80","author":"Marek","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000649","article-title":"Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH","volume":"9","author":"Stine","year":"2025","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tem.2026.01.008_bb0290","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2468-1253(24)00380-7","article-title":"Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective","volume":"10","author":"D\u00edaz","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0295","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/HEP.0000000000000941","article-title":"Physical exercise in liver diseases","volume":"83","author":"Zhang","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0300","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.eprac.2025.07.014","article-title":"American association of clinical endocrinology consensus statement: algorithm for management of adults with dyslipidemia \u2013 2025 update","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.tem.2026.01.008_bb0305","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.jacl.2024.04.001","article-title":"Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","volume":"18","author":"Bays","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.tem.2026.01.008_bb0310","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.01.008_bb0315","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.cgh.2024.10.025","article-title":"Resolution of metabolic dysfunction-associated steatohepatitis with no worsening of fibrosis after bariatric surgery improves 15-year survival: a prospective cohort study","volume":"23","author":"Lassailly","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0320","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/jgh.70084","article-title":"Efficacy of incretin-based therapies in patients with metabolic dysfunction-associated steatotic liver disease: an updated systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Liu","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0325","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.01.008_bb0330","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0335","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2026.01.008_bb0340","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tem.2026.01.008_bb0345","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s11695-023-06490-w","article-title":"Bariatric surgery is associated with alcohol-related liver disease and psychiatric disorders associated with AUD","volume":"33","author":"Alvarado-Tapias","year":"2023","journal-title":"Obes. Surg."},{"key":"10.1016\/j.tem.2026.01.008_bb0350","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.01.008_bb0355","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0168-8278(24)00708-6","article-title":"SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH\/MASH serial liver biopsy study","volume":"80","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0360","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2026.01.008_bb0365","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0370","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Saeed","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0375","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0380","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2026.01.008_bb0385","article-title":"Accelerated progression to cirrhosis and hepatic decompensation in metald and ALD compared to MASLD: a global study","volume":"30","author":"Piga","year":"2025","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0390","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S2468-1253(25)00188-8","article-title":"Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis","volume":"10","author":"Celsa","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2026.01.008_bb0395","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2025-100319","article-title":"Metabolic dysfunction and alcohol-associated liver disease (MetALD)","volume":"3","author":"Gao","year":"2025","journal-title":"eGastroenterology"},{"key":"10.1016\/j.tem.2026.01.008_bb0400","series-title":"Tackling NCDs: Best Buys and Other Recommended Interventions for the Prevention and Control of Noncommunicable Diseases","author":"World Health Organization","year":"2024"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026000081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026000081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:05:58Z","timestamp":1788793558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276026000081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1043276026000081"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2026.01.008","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MetALD at the crossroads of metabolic and alcohol-related liver disease","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2026.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}